GENOMTEC

PRESENTATION
INVESTOR

December 2024

GPW

The company is listed on
Warsaw Stock Exchange

Legal disclaimers

This document has been prepared for informational purposes only, contains only summary information and is not intended to be exhaustive, nor is it intended to be the sole basis for any analysis or evaluation. Genomtec SA makes no representations (express or implied) regarding the information presented in this document and no reliance should be placed on any information contained in this document, including the forecasts, estimates and opinions contained therein. Genomtec SA assumes no liability for any errors, omissions or irregularities contained in this document. It uses sources of information that Genomtec SA considers reliable and accurate, but there is no guarantee that they are exhaustive and fully reflect the facts. This document does not constitute advertising or an offer of securities in public trading. The document may contain forward-looking statements that constitute an investment risk or a source of uncertainty and may differ materially from actual results. Genomtec SA is not responsible for the effects of decisions made on the basis of this document. The responsibility rests solely with the user of the document. The work is protected by the Copyright and Related Rights Act. Reproduction, publication or distribution requires written consent of Genomtec SA

An international team, a combination of science and business

GENOMTEC

MANAGEMENT

Miron Tokarsky

Chairman of the Management Board,

Co-founder of the Company

Co-creator of Genomtec technology and patents
Doctor of Medical Sciences in the field of molecular biology.
Honored by Forbes in the "Leaders of the Future" ranking.

Michael Wachowski

Member of the Management Board,

Financial Director

14+ years of experience in: corporate finance, investment management and business consulting. He was an investment director in a Venture Capital fund.

international team of 20 experts

two locations: Wrocław and Kent (UK)

CO-FOUNDERS

Margaret Little-Masurian

Chief Research Officer

Over 10 years of experience in molecular biology. Head of the Department of Molecular Techniques at the Medical University of Wrocław. Author of scientific publications and co-author of Genomtec patents.

Henryk Roguszczak

Design Director

Author of patents and over 80 domestic and foreign scientific publications.

Previously an expert at the Wrocław University of Science and Technology at the Faculty of Microsystems, Electronics and Photonics. Coordinator of research activities in the field of photonics.

GENOMTEC

Technology

Genomtec SNAAT

Delivering innovative diagnostic technologies close to the patient – Point of Care

SNAAT technology

TEST SCOPE

- Infections
- Epidemiology
- Environmental testing

TESTING LOCATION

- Clinics
- Doctor's offices
- Emergency Department
- Patient transportation
- Airports

Genomtec is a MedTech company specializing in the development of advanced genetic diagnostics technologies.

What makes LAMP isothermal technology unique?

PCR	LAMP
Requires temperature cycling	Isothermal – one constant temperature
Requires 2 starters	Requires 6 starters
Free: usually over 1 hour	Fast: usually <30 min
Requires a separate reverse transcription step	Reverse transcription occurs together with the amplification step
Typical yield approx. 0.2 µg	Typical yield approx. 10-20 µg
Sensitive to inhibitors from the biological sample - it is necessary cleaning	Inhibitor-insensitive – native sample can be used biological
Requires thermal denaturation	The unraveling of the strands is caused by polymerase
Requires advanced thermal cycler	Compatible with both thermal cyclers and plate readers, and heating blocks
It allows to detect a specific DNA fragment at the level nanogram (10^{-9}g)	It allows to detect a specific DNA fragment at the level femtogram (10^{-15}g)
High specificity	Very high specificity due to greater coverage DNA/RNA segment amplified by primers

oncoSNAAT

Current standard

Suspicion cancer

Biopsy order

Biopsy cancer

Transport

Analytical phase

Insulation DNA/RNA

Preparation libraries to sequencing

Sequencing

Analysis bioinformatics

Therapeutic decision

Test result available for a doctor – application targeted therapy

48-72 hrs

A few to a dozen weeks

Genomtec



Ordering a study in at the moment of suspicion cancer

Analytical phase

Plasma transfer on the card



Placing the card in device

Starting the analysis

Test result available to the doctor – Application of therapy targeted

The effects of using isothermal technologies

SPEED AND HIGH PRECISION

- High accuracy results
- Carrying out multiple amplification reactions simultaneously (multiplexing)
- Easy procedure conducting a study

MOBILITY

- Small analyzer dimensions and compact card microfluidic
- Possibility of use outside the laboratory (POCT)
- Room temperature stability
- Low energy requirements

VERSATILITY

- Identification of pathogens such as viruses and bacteria.
- Identification of genetic variants (e.g. CDx, prediction).
- Possibility to connect multiple analyzers

LOW COST

- Simplified construction microfluidic card
- Relatively low cost of the analyzer and reagents
- Lower cost of analysis thanks to multiplexing technology

GENOMTEC

Change of structure organizational

Changes in the organizational structure of the company in connection with the M&A process

CURRENTLY:

GENOMTEC SA.

One company carries out all projects

- Adjustment down needs buyers
- Accelerate M&A transactions
- Increase in transaction value

AFTER CHANGE:



GENOMTEC

Current activities operational

M&A process status – synergy of business and R&D activities

Several dozen meetings

July 2023 - Present
Building a list of interested parties

Signing of contracts
NDA

Signing of confidentiality agreements with a number of interested entities.

5 areas interests

Exchange of data regarding technologies offered by both parties to NDA agreements.

- Environmental requirements and stability of use of the Genomtec ID platform (including temperature, humidity).
- Costs of producing large-scale reaction cards.
- Leverage amplification technologies owned by potential partners.
- Diagnostics acceleration capabilities using Genomtec ID. (Q4 2024)
- Methods for detecting genetic changes using isothermal technologies developed by Genomtec. (Q4 2024)

Environmental requirements and stability of use of the Genomtec ID platform (including temperature, humidity)

- **A series of tests and optimizations of algorithms controlling the non-contact heating system were carried out in an extended range of outside temperature and relative humidity.**
  - Temperature stabilization was achieved at**level +/- 0.15°C**with a temperature difference between heating zones of up to 5°C. In combination with the use of 3 heating zones we managed**cover the full temperature range for LAMP technology 60-70°C**



  - Confirmed**no influence of outside temperature changes**and**humidity**from the tested range on the efficiency of the heating system.
  - The stability of the heating system was confirmed between subsequent analyses.
  - The stability of the heating system over time has been confirmed.
- **Work on increasing the resolution of the heating system is coming to an end – more heating zones –**greater accuracy of the analyses performed.

Possibilities of accelerating diagnostics using Genomtec ID.

- In conjunction with the work focused on reducing the cost of producing the reaction card, at the request of one of the potential partners, the possibilities of using new reagents to shorten the test time were investigated.
  - It was carried out**several thousand reactions**allowing the use of proprietary primers from the RP5-Plex panel (influenza A, influenza B, RSV A, RSV B, SARS-CoV-2, M. pneumoniae, Ch. pneumoniae) in combination with new enzymes.
- The work also includes the development of a shortened protocol for isolating RNA viruses.
- The above activities aim to create a panel of viral infections with TAT ~15 min.

- **As part of the work carried out, the amplification time in the LAMP technique was shortened to <10 min. for viral pathogens along with an improvement in the detection limit.**
- Work is underway to optimize a shortened procedure for isolating genetic material.



Amplification curves for influenza A (top), B (middle) at 50 GE/reaction and for influenza A at 10,000 GE/reaction (bottom)



Status of the M&A process – reduction of production costs

Costs of producing large-scale reaction cards.

- **Discussions were held with a number of partners specializing in the production of lab-on-chip microfluidic systems.**
- **Two independent quotes (CDMO partners) were obtained related to scaling up mid-scale production – semi-automatic line and large scale – automatic line.**
- **In order to define the function of the production lines, it was necessary to determine the requirements related to the stabilization of reagents allowing them to be stored at room temperature.**
  - Several hundred amplification reactions were performed to determine the impact of a number of stabilization processes on the diagnostic parameters of the tests.
- **The work carried out allowed us to determine the requirements for production lines, along with their equipment and costs.**
- **Achieved over 70% reduction in production cost of card and reagents.**
- **Work also focused on optimizing reagent costs.**
  - Obtained**up to 80% reduction in reagent costs**.

Development of the Onco SNAAT project

500+

Conducted laboratory reactions Development of an original method for diagnosing single-nucleotide changes

cftDNA

Selection of sample volume parameters.
Start of work on DNA isolation method.

IP

Actions aimed at obtaining and extending intellectual property protection.

21.6M PLN

FENG PARP funding amount - completion of the grant project planned for the 1st half of 2027

Fundusze Europejskie dla Nowoczesnej Gospodarki

PARP Grupa PFR

The Genomtec project entitled: "Development of technology and an automatic system for detecting mutations in the field of clinical oncology based on the lab-on-chip solution and isothermal nucleic acid amplification techniques" was among 198 applications entered by PARP on the list of projects assessed positively in the SMART Path Measure FENG.01.01-IP.02-001/23/2023 under the European Funds for Modern Economy Programme.

* The recommended amount of funding for the project is approximately PLN 21.6 million with a total project budget of approximately PLN 40 million. If funding is received, the project will be implemented in the period from January 2024 to June 2027.

GENOMTEC

Market Potential
food safety

The State of the Microbiological Diagnostics Market

- Pathogens such as**Salmonella, Listeria monocytogenes and E. coli**pose a significant threat to food safety. In recent years, there has been an increase in the number of cases of Salmonella, E. coli and Listeria in food products.
- Millions of cases of infections caused by foodborne microorganisms occur every year.
- Problems with control: staff shortages (e.g. veterinarians), insufficient training of sanitary inspectors.
- Polish food was reported as one of the most frequently contaminated in the EU: in 2017, 87 notifications of unsafe food were received from Poland, and in the following years these numbers increased, respectively in 2018 - 131 cases, in 2019 - 203 cases, in 2020 over 273 cases.
- Growing demand for fast, accurate and affordable diagnostic tests in the food sector.

Source: Food safety control system in Poland – current status and desired directions of changes 2020, Supreme Audit Office

- Reports of contamination of Polish products constitute 13 percent of cases worldwide.
- In addition, the European Commission Audit showed that Sanitary Inspection inspectors did not have sufficient knowledge about taking swab samples to detect this bacteria. This is confirmed by the Report from the period 2017-2018, which indicates that 6.5% of veterinarians left work, which meant that over 60% of teams were unable to perform their tasks correctly.
- Poland, which is the seventh largest food exporter in the EU with a result of over EUR 30 billion per year and is responsible for food safety both on the Polish and international markets, but does not have effective legal methods, nor does it take sufficient actions to guarantee the safety of food introduced to the market.

Source: Food safety control system in Poland – current status and desired directions of changes 2020, Supreme Audit Office

Diagnostic methods

Microbiological cultures waiting time from 48h to >21 days

Rapid diagnostic tests low sensitivity and specificity complicated diagnostic process

Genetic identification

long waiting time >14 days, high cost of analysis Very often it is necessary to conduct pre-cultivation

Diagnostic methods

Salmonella

- **Standard:** PN-EN ISO 6579-1:2017-04
- **Methodology:** multi-step detection process, including biochemical and serological confirmations
- **Duration:** up to 7 days
- **Modern solutions:** molecular methods (Real Time-PCR, LAMP) allowing to shorten the diagnostic time

E. coli

- **Reference standard:** ISO 13136 (for STEC)
- **Assistive techniques:** identification of pathogenicity genes (molecular biology), cultivation on media
- **Other standards:**
  - PN-ISO 16649-1, 16649-2, 16649-3 (determination of beta-glucuronidase-positive E. coli)
  - PN-ISO 4831, 4832 (determination of coliform bacteria)

Listeria monocytogenes

- **Standards:** PN-EN ISO 11290-1:2017-07, 11290-2:2017-07
- **Process:** preincubation, cultivation on selective media (ALOA, PALCALM)
- **Confirmatory tests:** motility, hemolysis, carbohydrate breakdown

Diagnostic methods

Test Type	Sensitivity (%)	Specificity (%)	Limit detection (CFU/g or ml)	Time to obtain result	Cost (USD)
PCR (reaction chain polymerases)	95-99	98-100	1-10 CFU/g	1-4 hours	15-50
ELISA-test	85-90	90-95	10^3-10^4 CFU/g	2-6 hours	5-20
Tests Immunochrome graphic	80-85	85-90	10^4-10^5 CFU/g	10-30 minutes	2-10
Breeding bacterial	90-100	100	1-10 CFU/g	24-72 hours	1-5

Market forecasts

Market value: By 2030, the pathogen diagnostics market will grow to**9 USD billion.**

Quick tests(mainly antigenic) will increase from USD 3 billion (2021) to USD 5.8 billion (2030).

Growth of the molecular methods market:9% per annum.

GENOMTEC

Q&A session

investors@genomtec.com

genomtec.com

Genomtec ID: fast, cheap, portable, 5-pathogen test

GENOMTEC

❖ Genomtec ID –passive reaction card and simple design - a source of competitive advantage

GENOMTEC

Estimated price
€35

Competitive cost
production:without sensors,
chips, components
electronic and mobile

Cepheid,
Gene Expert

Average price
€35-50

Complex mechanical structure –
including valves, bushings
syringe, seals

Visby Medical

Average price
$50



Disposable
device
with electronics
and moving parts

Binx

Average price
$60 - 75



Expensive cartridge
with semiconductors and
sensors

Bosch
Vivalytic

Average price
€50-80

Complex construction –
multi-layer system
flow, membranes,
PCB, electrodes

Lucira Health

Average price
$40-45



Universal device
disposable with electronics
and heaters

M&A Process

Technology parameters sought by potential acquirers:



Clairfield Partners – M&A Advisor
has extensive experience in M&A transactions, including in the area of medical technology and biotechnology, including the genetic diagnostics sector.

Objective:
Establishing strategic partnerships, selling licenses and/or selling all or part of your intellectual property
and the technology associated with it.

Planned activities:

- identification and selection of potential buyers and partners.
- preparation of necessary materials and establishment of contacts with global companies from, among others, the sector of medical devices for in vitro diagnostics

- organization of the due diligence process,
- shaping the negotiation strategy
- coordinating the process of final talks related to a potential transaction